140 related articles for article (PubMed ID: 10383925)
1. Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects.
Weber C; Gasser R; Hopfgartner G
Drug Metab Dispos; 1999 Jul; 27(7):810-5. PubMed ID: 10383925
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects.
Weber C; Schmitt R; Birnboeck H; Hopfgartner G; van Marle SP; Peeters PA; Jonkman JH; Jones CR
Clin Pharmacol Ther; 1996 Aug; 60(2):124-37. PubMed ID: 8823230
[TBL] [Abstract][Full Text] [Related]
3. Relative bioavailability of a newly developed pediatric formulation of bosentan vs. the adult formulation.
Gutierrez MM; Nicolas LB; Donazzolo Y; Dingemanse J
Int J Clin Pharmacol Ther; 2013 Jun; 51(6):529-36. PubMed ID: 23611572
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist.
Dingemanse J; van Giersbergen PL
Clin Pharmacokinet; 2004; 43(15):1089-115. PubMed ID: 15568889
[TBL] [Abstract][Full Text] [Related]
5. Bosentan.
Chin K; Channick R
Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):175-82. PubMed ID: 15151466
[TBL] [Abstract][Full Text] [Related]
6. Absorption, metabolism, and excretion of [14C]imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects.
Ohmori S; Miura M; Toriumi C; Satoh Y; Ooie T
Drug Metab Dispos; 2007 Sep; 35(9):1624-33. PubMed ID: 17567733
[TBL] [Abstract][Full Text] [Related]
7. Absorption, distribution, metabolism, and excretion of N,N-diethyl-M-toluamide in the rat.
Schoenig GP; Hartnagel RE; Osimitz TG; Llanso S
Drug Metab Dispos; 1996 Feb; 24(2):156-63. PubMed ID: 8742226
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and preliminary safety data of a single oral dose of bosentan, a dual endothelin receptor antagonist, in cats.
Puza N; Papich MG; Reinero C; Chang CH; Yu DH; Sharp C; DeClue A
J Vet Pharmacol Ther; 2014 Apr; 37(2):192-5. PubMed ID: 24745065
[TBL] [Abstract][Full Text] [Related]
9. Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs.
Yamaguchi T; Nakajima Y; Mizobuchi M; Inazawa K; Kanazu T; Kadono K; Ohkawa T; Iwatani K
Arzneimittelforschung; 1998 Oct; 48(10):995-1006. PubMed ID: 9825117
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, tissue distribution, metabolism, and excretion of celecoxib in rats.
Paulson SK; Zhang JY; Breau AP; Hribar JD; Liu NW; Jessen SM; Lawal YM; Cogburn JN; Gresk CJ; Markos CS; Maziasz TJ; Schoenhard GL; Burton EG
Drug Metab Dispos; 2000 May; 28(5):514-21. PubMed ID: 10772629
[TBL] [Abstract][Full Text] [Related]
11. Absorption, metabolism, and excretion of darunavir, a new protease inhibitor, administered alone and with low-dose ritonavir in healthy subjects.
Vermeir M; Lachau-Durand S; Mannens G; Cuyckens F; van Hoof B; Raoof A
Drug Metab Dispos; 2009 Apr; 37(4):809-20. PubMed ID: 19131522
[TBL] [Abstract][Full Text] [Related]
12. Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers.
Weber C; Schmitt R; Birnboeck H; Hopfgartner G; Eggers H; Meyer J; van Marle S; Viischer HW; Jonkman JH
J Clin Pharmacol; 1999 Jul; 39(7):703-14. PubMed ID: 10392325
[TBL] [Abstract][Full Text] [Related]
13. Absorption, distribution, metabolism and excretion of [14C]ebastine after a single administration in rats.
Fujii T; Matsumoto S; Amejima H; Hatoyama T; Nakao M; Kagemoto A; Tanaka K; Miyazaki H
Arzneimittelforschung; 1994 Apr; 44(4):527-38. PubMed ID: 7912071
[TBL] [Abstract][Full Text] [Related]
14. In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide.
van Giersbergen PL; Treiber A; Clozel M; Bodin F; Dingemanse J
Clin Pharmacol Ther; 2002 Apr; 71(4):253-62. PubMed ID: 11956508
[TBL] [Abstract][Full Text] [Related]
15. Influence of severe renal dysfunction on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist.
Dingemanse J; van Giersbergen PL
Int J Clin Pharmacol Ther; 2002 Jul; 40(7):310-6. PubMed ID: 12139208
[TBL] [Abstract][Full Text] [Related]
16. Metabolism and excretion of the novel antipsychotic drug ziprasidone in rats after oral administration of a mixture of 14C- and 3H-labeled ziprasidone.
Prakash C; Kamel A; Anderson W; Howard H
Drug Metab Dispos; 1997 Feb; 25(2):206-18. PubMed ID: 9029052
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects.
Wrishko RE; Dingemanse J; Yu A; Darstein C; Phillips DL; Mitchell MI
J Clin Pharmacol; 2008 May; 48(5):610-8. PubMed ID: 18305126
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and metabolism of the new thromboxane A2 receptor antagonist ramatroban in animals. 1st communication: absorption, concentrations in plasma, metabolism, and excretion after single administration to rats and dogs.
Boberg M; Ahr HJ; Beckermann B; Bühner K; Siefert HM; Steinke W; Wünsche C; Hirayama M
Arzneimittelforschung; 1997 Aug; 47(8):928-38. PubMed ID: 9296279
[TBL] [Abstract][Full Text] [Related]
19. Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole.
van Giersbergen PL; Halabi A; Dingemanse J
Br J Clin Pharmacol; 2002 Jun; 53(6):589-95. PubMed ID: 12047483
[TBL] [Abstract][Full Text] [Related]
20. Lack of a pharmacokinetic interaction between oral treprostinil and bosentan in healthy adult volunteers.
Gotzkowsky SK; Dingemanse J; Lai A; Mottola D; Laliberte K
J Clin Pharmacol; 2010 Jul; 50(7):829-34. PubMed ID: 20133511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]